HUTCHMED (China) Limited (0013.HK)
HKD 23.0
(-0.22%)
HKD 23.0
(-0.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 26.58 Million USD | 116.77% |
| 2022 | -401.1 Million USD | -21.82% |
| 2021 | -329.26 Million USD | -80.04% |
| 2020 | -182.88 Million USD | -35.34% |
| 2019 | -135.13 Million USD | -64.68% |
| 2018 | -82.05 Million USD | -65.76% |
| 2017 | -49.5 Million USD | -14.1% |
| 2016 | -43.38 Million USD | -509.24% |
| 2015 | -7.12 Million USD | -22.0% |
| 2014 | -17 Million USD | -469.2% |
| 2013 | 12.04 Million USD | 123.28% |
| 2012 | 14.06 Million USD | -166.59% |
| 2011 | 11.31 Million USD | 276.99% |
| 2010 | 2.37 Million USD | 1823.32% |
| 2009 | -46.89 Thousand USD | 101.49% |
| 2008 | -9.57 Million USD | -68.94% |
| 2007 | -5.92 Million USD | -130.17% |
| 2006 | -2.51 Million USD | 32.39% |
| 2005 | -3.41 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -10.63 Million USD | 76.07% |
| 2024 Q2 | -10.63 Million USD | 0.0% |
| 2023 Q1 | 57.73 Million USD | 155.87% |
| 2023 FY | - USD | 116.77% |
| 2023 Q4 | -44.44 Million USD | 0.0% |
| 2023 Q3 | -44.44 Million USD | -176.98% |
| 2023 Q2 | 57.73 Million USD | 0.0% |
| 2022 Q2 | -96.18 Million USD | 0.0% |
| 2022 Q3 | -103.32 Million USD | -7.42% |
| 2022 FY | - USD | -21.82% |
| 2022 Q4 | -103.32 Million USD | 0.0% |
| 2022 Q1 | -96.18 Million USD | -6.34% |
| 2021 Q4 | -90.45 Million USD | 0.0% |
| 2021 Q3 | -90.45 Million USD | -12.32% |
| 2021 FY | - USD | -80.04% |
| 2021 Q2 | -80.53 Million USD | -27.43% |
| 2021 Q1 | -63.2 Million USD | -9.57% |
| 2020 Q3 | -57.68 Million USD | -26.29% |
| 2020 FY | - USD | -35.34% |
| 2020 Q1 | -32.49 Million USD | 12.48% |
| 2020 Q2 | -45.67 Million USD | -40.57% |
| 2020 Q4 | -57.68 Million USD | 0.0% |
| 2019 Q2 | -35.96 Million USD | 0.25% |
| 2019 Q1 | -36.05 Million USD | -55.78% |
| 2019 FY | - USD | -64.68% |
| 2019 Q4 | -37.12 Million USD | -6.95% |
| 2019 Q3 | -34.71 Million USD | 3.47% |
| 2018 Q3 | -13.91 Million USD | 44.41% |
| 2018 FY | - USD | -65.76% |
| 2018 Q2 | -25.03 Million USD | -0.04% |
| 2018 Q1 | -25.02 Million USD | -38.67% |
| 2018 Q4 | -23.14 Million USD | -66.32% |
| 2017 FY | - USD | -14.1% |
| 2017 Q4 | -18.04 Million USD | 0.0% |
| 2017 Q1 | -7.37 Million USD | 50.04% |
| 2017 Q3 | -18.04 Million USD | -144.6% |
| 2017 Q2 | -7.37 Million USD | 0.0% |
| 2016 FY | - USD | -509.24% |
| 2016 Q4 | -14.76 Million USD | 0.0% |
| 2016 Q3 | -14.76 Million USD | -99.22% |
| 2016 Q2 | -7.41 Million USD | 0.0% |
| 2016 Q1 | -7.41 Million USD | -1084.33% |
| 2015 Q1 | 432 Thousand USD | -97.89% |
| 2015 FY | - USD | -22.0% |
| 2015 Q4 | 753 Thousand USD | 105.73% |
| 2015 Q3 | -13.14 Million USD | -3142.13% |
| 2015 Q2 | 432 Thousand USD | 0.0% |
| 2014 Q2 | -1.89 Million USD | 0.0% |
| 2014 Q1 | -1.89 Million USD | 81.01% |
| 2014 Q4 | 20.48 Million USD | 202.5% |
| 2014 FY | - USD | -469.2% |
| 2014 Q3 | -19.98 Million USD | -952.28% |
| 2013 Q1 | -2.2 Million USD | 48.78% |
| 2013 Q2 | -2.2 Million USD | 0.0% |
| 2013 Q3 | 2.14 Million USD | 197.17% |
| 2013 Q4 | -10 Million USD | -566.64% |
| 2013 FY | - USD | 123.28% |
| 2012 FY | - USD | -166.59% |
| 2012 Q4 | -4.3 Million USD | 0.0% |
| 2012 Q3 | -4.3 Million USD | 0.0% |
| 2011 FY | - USD | 276.99% |
| 2010 FY | - USD | 1823.32% |
| 2009 FY | - USD | 101.49% |
| 2008 FY | - USD | -68.94% |
| 2007 FY | - USD | -130.17% |
| 2006 FY | - USD | 32.39% |
| 2005 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 82.326% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 99.104% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 120.523% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 76.641% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 152.922% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | 75.795% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 93.646% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | 65.313% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 201.578% |
| SSY Group Limited | 2.11 Billion HKD | 98.743% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 86.994% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 93.817% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 99.828% |